ArticleNature communications2020
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Post-Translational Modifications in Traumatic Brain Injury: Decoding the Proteomic Landscape and Molecular Mechanisms of Secondary Injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines.FEBS open bio · 2026Article
- Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3D.Nature communications · 2026Article
- OCTN2 Activates a Non-Canonical Carnitine Metabolic Pathway to Promote MASH-HCC Progression and Immunotherapy Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The antitumor effect of tlr4 inhibition in head and neck cancer cell lines.Scientific reports · 2025Article
- TET1 functions as a tumor suppressor in lung adenocarcinoma through epigenetic remodeling and immune modulation.Epigenetics & chromatin · 2025Article
- Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules.ACS chemical biology · 2024Article
- Advances of E3 ligases in lung cancer.Biochemistry and biophysics reports · 2024Review
- p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications.Biomedicines · 2024Review
- TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC.Oncogene · 2024Article
- The Role of Hydrogen Sulfide in the Localization and Expression of p53 and Cell Death in the Nervous Tissue in Traumatic Brain Injury and Axotomy.International journal of molecular sciences · 2023Article
- Acetylation halts missense mutant p53 aggregation and rescues tumor suppression in non-small cell lung cancers.iScience · 2023Article
- Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53.Journal of the American Chemical Society · 2023Article
- Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis.Scientific reports · 2022Article
- GOF Mutant p53 in Cancers: A Therapeutic Challenge.Cancers · 2022Review
- The positive regulatory loop of TCF4N/p65 promotes glioblastoma tumourigenesis and chemosensitivity.Clinical and translational medicine · 2022Article
- Expression of Protein Acetylation Regulators During Peripheral Nerve Development, Injury, and Regeneration.Frontiers in molecular neuroscience · 2022Article
- Oleuropein Attenuates Lipopolysaccharide-Induced Acute Kidney InjuryFrontiers in pharmacology · 2021Article
- Predictive Markers for Malignant Urothelial Transformation in Balkan Endemic Nephropathy: A Case-Control Study.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Li Ren KongCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore. csiklr@nus.edu.sg.ORCID http://orcid.org/0000-0001-7980-4666
Richard Weijie OngLaboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore, Singapore.
Tuan Zea TanCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.ORCID http://orcid.org/0000-0001-6624-1593
Nur Afiqah Binte Mohamed SallehCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Matan ThangaveluGenome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore.
Jane Vin ChanGenome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore.
Lie Yong Judice KohGenome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore.
Giridharan PeriyasamyGenome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore.
Jieying Amelia LauCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Thi Bich Uyen LeLaboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore, Singapore.
Lingzhi WangCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Miyoung LeeMedical Research Council Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Srinivasaraghavan KannanBioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore, 138671, Singapore.ORCID http://orcid.org/0000-0002-9539-5249
Chandra S VermaBioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore, 138671, Singapore.
Chwee Ming LimDivision of Surgical Oncology (Head and Neck Surgery), National University Cancer Institute, Singapore (NCIS), Singapore, 119074, Singapore.
Wee Joo ChngCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
David P Lanep53 Laboratory (p53Lab), Agency for Science, Technology, and Research (A*STAR), Singapore, 138648, Singapore.ORCID http://orcid.org/0000-0003-0551-3545
Ashok VenkitaramanMedical Research Council Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Huynh The HungLaboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore, Singapore.
Chit Fang CheokInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology, and Research (A*STAR), Singapore, 138673, Singapore.
Boon Cher GohCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore. phcgbc@nus.edu.sg.ORCID http://orcid.org/0000-0002-4107-102X
Agency for Science, Technology and Research · SGNational University of Singapore · SGNational Cancer Centre Singapore · SGUniversity of Cambridge · GBNational University Cancer Institute, Singapore · SG
Funding
Medical Research Council MC_UU_12022/1
Abstract
Gain of function (GOF) DNA binding domain (DBD) mutations of TP53 upregulate chromatin regulatory genes that promote genome-wide histone methylation and acetylation. Here, we therapeutically exploit the oncogenic GOF mechanisms of p53 codon 158 (Arg
Indexed as
AcetylationAnimalsAntineoplastic AgentsApoptosisCaspase 3Cell Line, TumorCell ProliferationCisplatinCodonEpigenesis, GeneticGain of Function MutationGene Expression Regulation, NeoplasticHumansHydroxamic AcidsMice, SCIDModels, BiologicalAntineoplastic AgentsbelinostatCaspase 3CisplatinCodonHydroxamic AcidsMutant ProteinsNF-kappa BPoly(ADP-ribose) PolymerasesProtein IsoformsSulfonamidesTopotecanTRAIP protein, humanTumor Suppressor Protein p53Ubiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.